Press Releases | Mylan http://newsroom.mylan.com/ MediaRoom Mylan Launches Generic Angiomax® Injection http://newsroom.mylan.com/2018-06-18-Mylan-Launches-Generic-Angiomax-R-Injection - Bivalirudin for Injection is an anticoagulant intended for use with aspirin - Mon, 18 Jun 2018 14:07:00 -0400 http://newsroom.mylan.com/2018-06-18-Mylan-Launches-Generic-Angiomax-R-Injection Mylan Provides Statement on Generic Advair Diskus® http://newsroom.mylan.com/press-releases?item=123580 Wed, 13 Jun 2018 16:12:00 -0400 http://newsroom.mylan.com/press-releases?item=123580 Americares Honors Mylan with Power of Partnership Award http://newsroom.mylan.com/2018-06-11-Americares-Honors-Mylan-with-Power-of-Partnership-Award Award Presented at HDA Business and Leadership Conference Mon, 11 Jun 2018 15:29:00 -0400 http://newsroom.mylan.com/2018-06-11-Americares-Honors-Mylan-with-Power-of-Partnership-Award U.S. FDA Approves Mylan and Biocon's Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta® http://newsroom.mylan.com/2018-06-04-U-S-FDA-Approves-Mylan-and-Biocons-Fulphila-TM-pegfilgrastim-jmdb-the-First-Biosimilar-to-Neulasta-R Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce the risk of infection following myelosuppressive chemotherapy Mon, 04 Jun 2018 16:52:00 -0400 http://newsroom.mylan.com/2018-06-04-U-S-FDA-Approves-Mylan-and-Biocons-Fulphila-TM-pegfilgrastim-jmdb-the-First-Biosimilar-to-Neulasta-R Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin® approved by FDA http://newsroom.mylan.com/2018-06-01-Mylan-and-Biocon-to-Present-New-Data-at-the-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting-Reinforcing-the-Efficacy-Safety-and-Immunogenicity-of-Ogivri-TM-the-first-biosimilar-for-Herceptin-R-approved-by-FDA Fri, 01 Jun 2018 17:18:00 -0400 http://newsroom.mylan.com/2018-06-01-Mylan-and-Biocon-to-Present-New-Data-at-the-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting-Reinforcing-the-Efficacy-Safety-and-Immunogenicity-of-Ogivri-TM-the-first-biosimilar-for-Herceptin-R-approved-by-FDA